Adam Feuerstein will be the featured guest on TSC Live at noon EDT Tuesday, Sept. 22. Send him your questions by: Emailing us at email@example.com; posting them on our Facebook page, facebook.com/thestreet; Tweeting us @thestreet_news with #tsclive; or posting them on the live show page in the comments section. Bookmark the TSC Live page now.
NEW YORK (
CHANGE IN RATINGS
upgraded at Morgan Stanley from Equal-weight to Overweight. $90 price target. Visibility is improving for the company's international growth strategy.
upgraded at Argus from Sell to Buy. $17 price target. Delay at Echelon Place will prove to be a wise choice.
downgraded at Barclays from Overweight to Equal-weight. $20 price target. Company business has less leverage in an economic recovery.
( CVH) downgraded at Buy to Hold at Citigroup. Valuation call, as the stock has outperformed the market and its peers year-to-date.
upgraded at Credit Suisse to Outperform. $80 price target. Company is the best positioned integrated oil name in the current cycle.
( ETEF) upgraded at Goldman from Neutral to Buy. Company is taking advantage of credit trends and benefiting from improved trading volume.
( GENZ) downgraded at Deutsche Bank. Rating lowered to Hold from Buy. Maintains $61 price target and 2009 EPS estimates of $2.41.
upgraded at JP Morgan. Rating raised to Overweight from Neutral. Price target raised to $25.50 from $10.00. Maintains 2009 EPS estimates of -$2.44.
rated new Outperform at FBR. $35 price target. Company is well capitalized and is leveraged to an improving economy.
upgraded at Piper from Neutral to Overweight. $22.50 price target. Company just signed its largest ever contract.
Procter & Gamble
upgraded at Citigroup from Hold to Buy. $66 price target. Company is changing its strategy and trying to be more aggressive to win back market share.
upgraded at Piper from Neutral to Overweight. $24 price target. Improving sales should drive margin expansion.
downgraded at Goldman from Neutral to Sell. Short term interest rates will likely not move up until 2011, which hampers two of the company's main revenue drivers.
upgraded at Merrill/BofA from Underperform to Buy. $30 price target. Company should see a dramatic earnings recovery, beginning in the second half of 2009, driven by tight NAND supply.
upgraded at JP Morgan. Rating raised to Overweight from Neutral. Raises price target to $29 from $17. Maintains 2009 EPS estimates of -$4.45.
upgraded at Wedbush from Neutral to Outperform. $23 price target. New Cloud mattress line doubles the company's addressable market.
downgraded at Citigroup from Buy to Hold. Company is facing Medicare headwinds and mixed commercial pricing.
upgraded at Citigroup from Hold to Buy. Company has become more disciplined with its pricing. $70 price target.
STOCK COMMENTS / EPS CHANGES
target raised at Goldman to $60. Company announced a new oil discovery in Africa. Neutral rating.
target raised at UBS to $46. Company should meet earnings expectations next week and booking volumes have likely picked up in recent weeks. Buy rating.
target raised at UBS to $18. Companies are cutting back on capital spending. Neutral rating.
target raised at Morgan Stanley to $48. Aerospace and defense markets are poised to grow from current levels. Equal-weight rating.
estimates, target boosted at Oppenheimer. Shares now seen reaching $41. Estimates also raised, following positive channel checks in Asia. Outperform rating.
target boosted at UBS to $26. Company is spending less on CapEx and interactive advertising is starting to pay off. Neutral rating.
target boosted at FBR Shares of DFS now seen reaching $19. Company has strong earnings momentum. Outperform rating.
target raised at Collins Stewart to $600. Ad spending has begun to rebound and consensus earnings estimates appear to be low. Buy rating.
2009 estimates raised at Barclays to reflect higher returns from principal investments. Equal-weight rating and $165 price target.
numbers boosted at Merrill/BofA Shares of HMA now seen reaching $9.50. Estimates also raised to reflect better margins in the hospital industry. Buy rating.
estimates raised at Morgan Stanley. HSP estimates were increased through 2011. Company hosted a positive analyst meeting and has several growth vehicles. Equal-weight rating.
estimates, target boosted at Goldman. Shares of IHS now seen reaching $58. Estimates also raised, to reflect improving business trends. Neutral rating.
Illinois Tool Works
numbers raised at Morgan Stanley Shares to $36. Estimates also boosted, to match the company's new guidance. Equal-weight rating.
numbers raised at Goldman. Estimates were boosted through 2011. Company is seeing improved glass volumes. Buy rating and new $47 price target.
( OSIP) target raised at Goldman. Shares now seen reaching $38. New Tarceva patent reduces the risk for generic competition. Neutral rating.
( PALM) estimates, target lowered at Merrill/BofA. Shares of PALM now seen reaching $20, according to Merrill Lynch/Bank of America. Estimates also reduced, to reflect lower prices and the secondary offering. Buy rating.
( PCU) numbers raised at Morgan Stanley. Shares of PCU now seen reaching $34. Estimates also boosted, to reflect higher copper prices. Equal-weight rating.
target cut at Merrill/BofA to $29. Gaming revenue has been soft the past two quarters. Neutral rating.
target increased at UBS to $24. Stock should begin to trade on 2010 earnings, especially as bookings are starting to recover.
estimates, target lowered at UBS. Estimates were cut through 2010. Company is running out of room to cut costs. Neutral rating and new $4 price target.
estimates, target boosted at Goldman. SLH estimates increased through 2012. Recent acquisition should be accretive to earnings. Neutral rating and new $31 price target.
numbers raised at Credit Suisse. Estimates were increased through 2010. Company now has a higher share, following a much needed capital raise. Underperform rating and new $3 price target.
estimates cut at FBR through 2010. Capital raise is dilutive, but will ultimately benefit the company. Market Perform rating and $3 price target.
estimates cut through 2010 at UBS. Recent checks are showing declining U.S. sales volumes. Buy rating and $58 price target.
Time Warner Cable
target increased at UBS to $42. Cable could take market share in the second half of the year, and capital spending is down across the board. Neutral rating.
target increased at Barclays to $24. Checks show that the company is seeing strong demand. Overweight rating.
This article was written by a staff member of TheStreet.com.